NEW YORK (360Dx) – A team of researchers at the University of Utah is developing a point-of-care platform using alpha-fetoprotein, a biomarker already in use in laboratory tests, to detect liver cancer. They have built a proof-of-concept system made possible by a nanoplasmonic coating that amplifies its signal and enhances its level of detection, the researchers said.
Get the full story with
360Dx Premium
Only $95 for the
first 90 days*
360Dx Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives
Never miss another important industry story.
Try 360Dx Premium now.
You may already have institutional access!
Check if I qualify.
Already a 360Dx or GenomeWeb Premium member?
Login Now.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.